Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase Ib/IIa Trial With Expansion Cohorts in Melanoma and Soft Tissue Sarcoma Patients.
Latest Information Update: 21 Mar 2025
At a glance
- Drugs InCVAX N dihydro galacto chitosan (Primary)
- Indications Malignant melanoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 18 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 12 Apr 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 12 Apr 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2025.